A drug described as a landmark in treating multiple sclerosis is being reviewed for use in Europe. Trials suggest that Ocrelizumab can slow damage to the brain in two forms of MS, which offers a lot of hope for the future.

PEOPLE with crippling illnesses — including multiple sclerosis and cancer patients, — are among those being forced to break the law by using cannabis for medicinal purposes.